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Abstract
Background: Several receptor tyrosine kinases (RTKs) such as EGFR, FGFR, TRK, and VEGFR are capable of localizing in 
the cell nucleus in addition to their usual plasma membrane localization. Recent reports also demonstrate that nuclear-
localized RTKs have important cellular functions such as transcriptional activation. On the basis of preliminary 
bioinformatic analysis, additional RTKs, including receptor tyrosine kinase-like orphan receptor 1 (Ror1) were predicted 
to have the potential for nuclear subcellular localization. Ror1 is a receptor protein tyrosine kinase that modulates 
neurite growth in the central nervous system. Because the nuclear localization capability of the Ror1 cytoplasmic 
domain has not been reported, we examined the cellular expression distribution of this region.
Results: The Ror1 cytoplasmic region was amplified and cloned into reporter constructs with fluorescent tags. 
Following transfection, the nuclear distribution patterns of transiently expressed fusion proteins were observed. Serial 
deletion constructs were then used to map the juxtamembrane domain of Ror1 (aa_471-513) for this nuclear 
translocation activity. Further site-directed mutagenesis suggested that a KxxK-16 aa-KxxK sequence at residues 486-
509 is responsible for the nuclear translocation interaction. Subsequent immunofluorescence analysis by 
cotransfection of Ran and Ror1 implied that the nuclear translocation event of Ror1 might be mediated through the 
Ran pathway.
Conclusions: We have predicted several RTKs that contain the nuclear localization signals. This is the first report to 
suggest that the juxtamembrane domain of the Ror1 cytoplasmic region mediates the translocation event. Ran GTPase 
is also implicated in this event. Our study might be beneficial in future research to understand the Ror1 biological 
signaling pathway.
Background
Receptor tyrosine kinases (RTKs) are transmembrane
molecules situated at the cellular surface whose function
is to detect their specific cognate ligands in the extracel-
lular milieu. RTKs are critical signal-transduction media-
tors that regulate many essential cellular activities
including growth and differentiation. In the usual signal-
transduction pathways, RTKs need to relay in a stepwise
manner the signals from cellular surface through other
signaling molecules, such as nonreceptor tyrosine kinases
and serine/threonine kinases. In addition to the antici-
pated cellular surface localization of RTKs, intriguingly,
recent reports have indicated that some of these receptor
kinases can be translocated inside the nucleus and may
constitute newly identified biochemical signals by them-
selves [1-3]. These RTKs include the EGFR family (EGFR
[4,5], ErbB-2 [6,7], ErbB-3 [8], ErbB-4 [9-11]), FGFR fam-
ily (FGFR1 [12-14], FGFR3 [15]), TRKA [16,17], and
VEGFR2 [18,19].
Although the details of the biological functions of these
nuclear translocated RTKs are not understood fully, stud-
ies have indicated the unique biochemical roles of RTKs
when trafficked into the nucleus. Membrane RTKs are
known to participate in the signal transduction pathways
including the Ras-MAPK pathway, IP3/DAG pathway,
and PI3K pathway [20,21]. By contrast, nuclear ErbBs can
function as transcription modulators in addition to the
protein kinase signal transducer [22]. For example,
nuclear EGFR interacts with STAT5 or STAT3 to transac-
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tivate the expression of the Aurora-A or nitric oxide syn-
thase (iNOS) genes, respectively [5,23]. Nuclear EGFR
can also function as a protein tyrosine kinase to phospho-
rylate Tyr 211 of PCNA, which increases the stability of
chromatin-bound PCNA protein [24]. Several recent
studies indicate that the nuclear localization of the ErbB
proteins can be a pathological feature in tumors such as
breast carcinoma, oropharyngeal squamous cell carci-
noma, and ovarian cancer tumors [25-29].
Another study of RTKs showed that activation of the
tyrosine hydroxylase gene promoter by nuclear FGFR1
and its natural ligand (FGF-2) is mediated through the
cAMP-responsive element (CRE) complexes in addition
to the usual intermediate signaling kinase molecules [13].
Learning more about the RTK nuclear localization pro-
cess and the underlying mechanisms would lead to a bet-
ter understanding of the modulatory functions of RTKs
in cells. In this study, we used bioinformatic tools to scan
all known human RTKs for their potential to localize in
the nucleus, and we conducted molecular experiments to
dissect the nuclear localization domain of one RTK,
receptor tyrosine kinase-like orphan receptor 1 (Ror1).
In our preliminary analysis, we first predicted the
potential RTK protein subcellular locations using the
PSORT II program. Our results indicated that several
additional RTKs might also be capable of localizing in the
nucleus, including the ROR RTK family. The ROR family
comprises two structurally related RTK genes, Ror1 and
Ror2, which share an overall 58% amino acid identity.
Rors were first cloned from a neuroblastoma cell line
using a polymerase chain reaction (PCR)-based
approach, which showed a region that is strongly homol-
ogous to the tyrosine kinase domain of the Trk family
[30]. Rors are evolutionally conserved among Caenorhab-
ditis elegans, Aplysia [31], Drosophila melanogaster [32],
mice [33], rats, cows, dogs, chimpanzees, and humans.
The ligand of Ror2 is Wnt-5A [34], whereas Ror1 remains
an orphan receptor protein tyrosine kinase without any
known interacting ligand molecules.
Ror1 and Ror2 are newly identified receptor tyrosine
kinases to have function involved in development in
mammalian central neurons. The Rors protein accumu-
lates in the process of synapse formation and concen-
trated in the growth cone of the immature neuron [35]. In
addition, knockdown of Ror1 or Ror2 expression leads to
a shorter and less branched neurite extension phenome-
non [36]. Some reports suggest that Ror1 and Ror2 have
different subcellular localizations, respectively. Ror1
associates with F-actin microfilament, whereas Ror2 co-
localizes with microtubules [37]. More studies are needed
to reveal the biological functions of ROR RTKs. Here, we
report on the confirmation of the nuclear localization
potential of this RTK family and our characterization of
the critical region involved in the nuclear translocation of
Ror1.
Results
Prediction of nuclear-localized RTKs
To learn more about the nuclear distribution of RTKs in
cells, we used the PSORT II program to predict the
nuclear localization probabilities of all human RTKs. The
PSORT II program was developed by Dr. Nakai's group
(Human Genome Center, Institute for Medical Science,
University of Tokyo, Japan) using the k-nearest-neighbor
method. The k-nearest-neighbor method is a pattern-rec-
ognition algorithm in which k is a predefined parameter.
The percentage of proteins whose nuclear localization
sites are correctly predicted is up to 90.7% [38]. Protein
subcellular prediction by PSORT II indicated that several
RTKs could localize in the nucleus. Table 1 shows the
predicted nuclear-localized RTKs including the EGFR,
FGFR, ROR, VEGFR, AATYK, and TRK RTK families.
Some reports have demonstrated that members of the
EGFR, FGFR, VEGFR, and TRK families localize to the
nucleus [4-19].
Based on the PSORT II NNCN score (Table 1), the
ROR family RTKs were considered to have good potential
for nuclear localization. The NNCN algorithm is used to
distinguish the protein tendency to be in either the
nucleus or the cytoplasm based on its amino acid compo-
sition [39]. We also performed further prediction analysis
using other bioinformatics tools (subnuclear [40],
ESLpred [41], SubLoc [42], and NpPred [43]). These bio-
informatics tools employ a range of different algorithms
to perform the prediction: subnuclear is based on the
amino acid composition and uses the dipeptide and trip-
eptide encoding method; ESLpred is based on the physic-
ochemical properties, amino acid composition, and
dipeptide composition of proteins; SubLoc is based on
the amino acid composition; and NpPred is based on the
amino acid, dipeptide, and split composition of proteins.
All programs supported the concept that the cytoplasmic
region of Ror1 protein has a good nuclear localization
potential (Additional file 1). Encouraged by the in silico
prediction results, we decided to further examine the cel-
lular expression distribution of the ROR proteins in vivo.
ROR RTK expression in various cell lines
Because Ror1 is an orphan receptor about which little is
known, we first examined the expression pattern of
endogenous Ror1 in various human tumor cell lines of
different tissue origins. Specific PCR primers were
designed to amplify a fragment (CDS: 2169-2311) of the
Ror1 transcript (NCBI Reference Sequence:
NM_005012). Our screening result identified HT-29
colon cancer cells having the highest Ror1 mRNA expres-Tseng et al. BMC Cell Biology 2010, 11:48
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sion level (Additional file 2). Further examination of
human colorectal cancer samples revealed higher expres-
sion of Ror1 in colorectal cancer tissues than in adjacent
normal colon tissues (data not shown). In most of the cell
lines examined, Ror1 seemed to have a higher or similar
expression level compared with Ror2, except in MCF-7
breast cancer cells.
Determination of nuclear localization domain of the 
cytoplasmic region of Ror1
To explore the nuclear localization potential of the Ror1
cytoplasmic region, we first generated plasmid chimeric
fusion constructs (see Methods) containing HcRed fluo-
rescent tag protein and the cytoplasmic region of either
Ror1 (NCBI Reference Sequence: NP_005003.2) or Ror2
(NCBI Reference Sequence: NP_004551.2) (Figure 1).
The localization of the fusion proteins was assessed by
detecting the far-red fluorescence emitted by the HcRed
fusion protein tags. The HcRed control vector showed an
overall homogenous distribution pattern. By contrast, the
Ror1 and Ror2 fusion proteins showed a nuclear localiza-
tion pattern following transfection (Figure 1). The
HcRed-Ror1 fusion protein had a unique patched subnu-
clear localization pattern in cells, whereas the HcRed-
Ror2 protein showed a more homogenous nuclear local-
ization pattern. Our data confirmed that the cytoplasmic
regions of Ror1 and Ror2 RTKs contain putative nuclear
localization signal domains. Because of the good homol-
ogy between Ror1 and Ror2, we selected the Ror1 gene
for subsequent experiments.
Because of the weak but noticeable nuclear expression
pattern of HcRed protein in the control vector, we opted
to switch to the human influenza hemagglutinin (HA)-
tag vector for subsequent studies. To further dissect the
domains responsible for the nuclear localization of Ror1,
we constructed several Ror1 deletion constructs fused
with the HA tag (Additional file 3). Ror1F1 encodes 185
amino acids of the N-terminal Ror1 cytoplasmic region,
Ror1F2 encodes 306 amino acids of the C-terminal Ror1
cytoplasmic region, and Ror1F3 and Ror1F4 contained
the Ror1 cytoplasmic region with the deletion of the N-
Table 1: Summary of nuclear-localized RTKs by PSORT II prediction
PSORT II results (NNCN score) References
EGFR family: EGFR Nuclear (70.6) Dittmann et al., 2005 [46]; Dittmann et al., 2008 [47]; Hoshino et al., 2007 [48]; Hsu 
and Hung, 2007 [4]; Hu et al., 2007 [49]; Hung et al., 2008 [5]; Lo et al., 2006a [50]; 
Lo et al., 2005 [23]; Lo et al., 2006b [51]; Lo and Hung, 2007 [52]
ERBB-2 Cytoplasmic (55.5) Xie and Hung, 1994 [6]; Giri et al., 2005 [7]; Wang et al., 2004 [53]
ERBB-3 Nuclear (70.6) Cheng et al., 2007 [8]
ERBB-4 Nuclear (55.5) Feng et al., 2009 [11]; Ni et al., 2003 [9]; Sundvall et al., 2007 [54]; Williams et al., 
2004 [10]
FGFR family: FGFR1 Nuclear (55.5) Kilkenny and Hill, 1996 [12]; Myers et al., 2003 [14]; Peng et al., 2002 [13]; 
Stachowiak et al., 1996 [55]
FGFR3 Cytoplasmic (89) Johnston et al., 1995 [15]
ROR family: ROR1 Nuclear (89) None reported
ROR2 Nuclear (70.6) None reported
VEGFR family: VEGFR1 Nuclear (70.6) None reported
VEGFR2 Cytoplasmic (76.7) Pillai et al., 2005 [18]; Zhang et al., 2005 [19]
AATYK family: LMTK2 Nuclear (89) None reported
TRK family: NTRK1 Cytoplasmic (94.1) Bonacchi et al., 2008 [17]; Gong et al., 2007 [56]; Lee et al., 1998 [16]Tseng et al. BMC Cell Biology 2010, 11:48
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terminal 61 residues and 18 residues, respectively. Ror1F3
encodes 424 amino acids, and Ror1F4 encodes 467 amino
acids. Following transfection, proper expression of each
deletion construct was verified by immunoblot analysis
(Additional file 4).
The subcellular protein distributions of these Ror1
deletion constructs were identified using confocal micro-
scopic analysis (Figure 2). As expected, the fusion con-
struct containing the full-length cytoplasmic region of
Ror1 localized mainly in the nucleus. The negative con-
trol plasmid construct carrying the HA-PKM2 (pyruvate
kinase type M2) fusion protein showed only the cytoplas-
mic distribution pattern. Among the deletion constructs,
the Ror1F1 fragment (aa_453-637) localized mainly in the
nucleus. By contrast, the Ror1F2 fragment (aa_632-937)
localized only in the cytoplasm. Similarly, the Ror1F3
fragment (aa_514-937) also showed a reduced nuclear
localization pattern compared with the full cytoplasmic
Ror1 construct or Ror1F1 fragment. By contrast, Ror1F4
(aa_471-937) restored the ability to localize in the
nucleus. The Ror1F4 fragment was constructed by adding
the 471-513 amino acid sequence to the N-terminal of the
Ror1F3 fragment. These data suggest that the 471-513
amino acid sequence may be responsible for the observed
nuclear localization capability of Ror1 RTK.
B e c a u s e  R o r 1  w a s  r e p o r t e d  t o  i n t e r a c t  w i t h  t h e
cytoskeleton and because it colocalizes with F-actin dur-
ing stress fiber formation, we then used rhodamine phal-
loidin to examine the actin stress fiber formation in these
serial deletion constructs. The pericytoplasmic mem-
brane localization of Ror1 fusion proteins and colocaliza-
tion with F-actin stress fiber were observed in HA-Cyto.
Ror1 (aa_453-937) construct. The ratio of nuclear distri-
bution of each Ror1 deletion construct was calculated by
quantitatively determining the mean percentage of fluo-
rescein isothiocyanate (FITC) fluorescence intensity from
30 randomly selected cells using the MetaMorph analysis
program (Molecular Devices, Inc.) (Figure 3). In brief,
our result suggested that the 471-513 amino acid motif
located within the juxtamembrane domain is the region
responsible for the observed nuclear translocation activ-
ity. This region is called Ror1 NLdomain hereafter.
Because no typical NLS signal peptide sequences are
found readily in the Ror1 cytoplasmic region, we exam-
ined this region for other possible motifs. Typically, this
NLS comprises one or more short sequences of positively
charged lysines or arginines. The Ror1 NLdomain does
contain a KxxK-16 aa-KxxK bipartite basic charged
amino acid pattern. To confirm that this region is truly
responsible for the Ror1 nuclear localization, we tried to
mutate the four lysines into alanines within this NLdo-
main region. Residues 486, 489, 506, and 509 were
mutated accordingly (illustrated in Additional file 5). The
Ror1 nuclear localization was abolished in the mutant
constructs examined (Figure 4), suggesting that all four
lysine residues are important to the Ror1 nuclear distri-
Figure 1 Ror1/2 mutant with the truncation of the ligand-binding and transmembrane domains are capable of nuclear transport. AGS and 
HR cells were transfected with the cytoplasmic part of Ror1/2 whose N-terminal was HcRed-tagged or with a vector control, and then analyzed by 
fluorescence confocal microscopy. The protein size of HcRed only is about 30 kDa; and the size of the HcRed-tagged Ror1/2 is about 85 kDa.Tseng et al. BMC Cell Biology 2010, 11:48
http://www.biomedcentral.com/1471-2121/11/48
Page 5 of 12
bution pattern. Our results suggest that the NLdomain
located at the juxtamembrane (aa_471-513) region of the
Ror1 cytoplasmic domain contributes to the nuclear
translocation function.
Nuclear translocation of Ror1 might be mediated by the 
RanGTP pathway
The nucleotide-bound state of the small GTPase Ran
plays a key role in nuclear transport [44]. We examined
the possible involvement of such a pathway in the trans-
portation of Ror1 RTK into the nucleus. A dominant-neg-
ative mutant of Ran (RanQ69L), which is deficient in
GTPase activity, prevents the nuclear import of target
proteins [7]. Confocal immunofluorescence analysis
showed increased expression of the Ror1 fusion protein
in the nucleus of cells cotransfected with wild-type Ran
protein but not in cells cotransfected with the control
vector. By contrast, the dominant-negative RanQ69L
mutant showed reduced nuclear localization of Ror1
fusion protein (Figure 5). Quantification of the Ror1
fusion protein distribution in transfected cells showed
that Ran GTPase plays a major role in the nuclear translo-
cation of Ror1 RTK (Figure 6).
Discussion
In this study, we reported that the cytoplasmic region of
the transmembrane RTK Ror1 was able to translocate
into the nucleus. This nuclear distribution pattern was
similar to that of TrkA RTK. TrkA is a nerve growth fac-
tor receptor that shows a predominant nuclear and peri-
nuclear localization resembling the small dense core
carrier vesicles [17]. We also observed that cytoplasmic
Ror1 formed a number of dense particles near the outer
nuclear membrane. Interestingly, Ror1 was originally
cloned from the homologous cytoplasmic region of TrkA.
The role of the juxtamembrane 471-513 region of Ror1 in
determining the nuclear localization identified in this
study response to the role of the intracellular portion of
TrkA. This conclusion is supported by the evidence
showing that nuclear TrkA is recognized only by antibod-
ies against the intracellular region but not by antibodies
against the extracellular domain [17].
The juxtamembrane regions of the EGFR family are
critical for the nuclear localization of their proteins. The
putative NLS in the juxtamembrane domain is conserved
Figure 2 Identification of the minimal Ror1 domain that plays a 
critical role in nuclear accumulation. Confocal microscopic analysis 
was used to detect subcellular localization of Ror1 fragments. HR cells 
were transfected for 24 hours with indicated Ror1 fragments and 
stained with anti-HA monoclonal antibody (green) followed by a fluo-
rescent (FITC) secondary antibody and with phalloidin rhodamine 
(red). DAPI staining shows the nucleus. PKM2, a known cytoplasmic 
protein, served as a negative control.
Figure 3 Quantification of the subcellular distribution ratios of 
different Ror1 fragments. The mean percentage of FITC fluorescence 
in the nuclear or cytoplasmic compartments for each construct was 
determined by analyzing the FITC intensity from 30 randomly selected 
cells.Tseng et al. BMC Cell Biology 2010, 11:48
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among the EGFR family. For example, the putative EGFR
NLS sequence is aa_669-RRRHIVRKRTLRR [4], the
putative ErbB2 NLS sequence is aa_676-KRRQQKIRKY
TMRR [7], the putative ErbB-3 NLS sequence is aa_669-
RRQKQNKRAMRR, and the putative ErbB-4 NLS
sequence is aa_676-RRKQSIKKKRALRR [10]. We dis-
covered that the 471-513 motif of Ror1 also localizes to
the juxtamembrane domain, implying that the nuclear
translocation of RTKs might be mechanistically similar.
However, there is no traditional nuclear-localized signal
sequence such as in the EGFR cases. We found the KxxK-
16 aa-KxxK bipartite pattern in this region and showed
that it is functional in Ror1 nuclear localization. The 3D-
structure modeling of the cytoplasmic part of Ror1
showed that the mapped Ror1 juxtamembrane 471-513
region is exposed at the outer part of the molecule, imply-
ing a greater opportunity to be recognized by interacting
proteins (Additional file 6).
Nuclear localized RTKs are found to be present as full-
length protein (ErbB-1, ErbB-3 and FGFR-1) or prote-
olytic cytoplasmic fragments (ErbB-4) [1]. In the case of
ErbB-4 RTK, it is cleaved by the metalloprotease and
gamma-secretase following the binding of its ligand [45].
The cleaved cytoplasmic region of ErbB-4 is then translo-
cated into the nucleus. This process is similar to the one
operated in the Notch signaling pathway [46]. In this
study, our attempts to detect the endogenous Ror1
expression using rat-anti Ror1 antibody showed a small
truncated form of Ror1 (~40 kD) in several cancer cell
lines (data not shown). The level of this possible trun-
cated fragment was diminished in subsequent si-Ror1
knockdown experiments. We propose that Ror1 is trans-
located into the nucleus and that this translocation is
mediated by the cleavage-releasing mechanism in addi-
tion to the Ran GTPase pathway.
Figure 4 Site-directed mutagenesis on Ror1 NLdomain unveils one nuclear localization signal. HR cells were transfected with indicated Ror1 
mutants and analyzed using anti-HA monoclonal antibody (green) followed by a fluorescent (FITC) secondary antibody. DAPI staining shows the nu-
cleus.Tseng et al. BMC Cell Biology 2010, 11:48
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Conclusions
Our study showed that the cytoplasmic region of Ror1
might be localized in the nucleus in human cancer cell
lines. Following the analysis using deletion constructs,
the juxtamembrane domain comprising 471-513 residues
of Ror1 was determined to be responsible for nuclear
translocation. The nuclear localization of Ror1 was
enhanced further by cotransfection of Ran wild-type pro-
tein but not by the mutant construct.
Methods
Cell lines
HR and AGS (human gastric cancer cell line) cells were
maintained in Dulbecco's Modified Eagle Medium
(DMEM) (12100-038, Invitrogen) plus 10% fetal bovine
serum (04-001-1A, Biological Industries) and grown at
37°C in 5% CO2. Cultures were passaged when they
reached 80% confluence.
Plasmid construction
pHcRed1-C1_cyto. Ror1 (CDS#1357-2814) vector was
constructed by cloning the 1,458 bp cDNA fragment con-
taining the cytoplasmic part coding for the sequence of
human Ror1 into the XhoI and KpnI site downstream of
the cytomegalovirus (CMV) immediate early promoter of
the pHcRed1-C1 plasmid (Clontech). The insert is
expressed as fusion with the C-terminus of HcRed1.
pHcRed1-C1_cyto. Ror2 (CDS#1333-2832) vector was
constructed by cloning the 1,500 bp cDNA fragment con-
taining the cytoplasmic part coding for the sequence of
human Ror2, which was digested from the pGEMT
Easy_cyto. Ror2 plasmid into the SalI and SacII site
downstream of the CMV immediate early promoter of
the pHcRed1-C1 plasmid (Clontech). The insert is
expressed as fusion with the C-terminus of HcRed1.
pXJN-HA_cyto. Ror1 (CDS#1357-2814) vector was
constructed by cloning the 1,458 bp cDNA fragment con-
taining the cytoplasmic part coding for the sequence of
human Ror1 into the HindIII and SmaI site downstream
of the CMV promoter of the pXJN-HA plasmid. The
insert is expressed as fusion with the C-terminus of the
HA tag.
pXJN-HA_Ror1F1 (CDS#1357-1911) vector was con-
structed by cloning the 555 bp cDNA fragment contain-
ing the cytoplasmic part coding for the sequence of
human Ror1 into the HindIII and SmaI site downstream
of the CMV promoter of the pXJN-HA plasmid. The
insert is expressed as fusion with the C-terminus of the
HA tag.
Figure 5 Confocal microscopy analysis of increased nuclear import of Ror1 by cotransfection with wild-type Ran. The flag-tagged WT Ran or 
empty vector control (-) was cotransfected into HR cells with the Ror1 constructs. The protein distribution was analyzed by confocal microscopy.Tseng et al. BMC Cell Biology 2010, 11:48
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pXJN-HA_Ror1F2 (CDS#1894-2814) vector was con-
structed by cloning the 921 bp cDNA fragment contain-
ing the cytoplasmic part coding for the sequence of
human Ror1 into the HindIII and SmaI site downstream
of the CMV promoter of the pXJN-HA plasmid. The
insert is expressed as fusion with the C-terminus of the
HA tag.
pXJN-HA_Ror1F3 (CDS#1540-2814) vector was con-
structed by cloning the 1,275 bp cDNA fragment contain-
ing the cytoplasmic part coding for the sequence of
human Ror1 into the HindIII and SmaI site downstream
of the CMV promoter of the pXJN-HA plasmid. The
insert is expressed as fusion with the C-terminus of the
HA tag.
pXJN-HA_Ror1F4 (CDS#1411-2814) vector was con-
structed by cloning the 1,404 bp cDNA fragment contain-
ing the cytoplasmic part coding for the sequence of
human Ror1 into the HindIII and SmaI site downstream
of the CMV promoter of the pXJN-HA plasmid. The
insert is expressed as fusion with the C-terminus of the
HA tag.
To generate NLS mutants of Ror1, specific alanine
mutations were constructed by site-directed mutagenesis
using the two-round PCR method [45]. The resulting
PCR products were cloned into the pXJN-HA plasmid.
pXJN-HA_Ror1F4 (CDS#1411-2814)K486A, K489A vector
has two mutations in the first basic amino acid cluster in
the Ror1 NLdomain. The mutations include CDS#
1456AAATGCA and 1465AAATGCA. The fragment was
constructed by cloning the 1,404 bp cDNA containing the
cytoplasmic part coding for the sequence of human Ror1
into the HindIII and SmaI site downstream of the CMV
promoter of the pXJN-HA plasmid. The insert is
expressed as fusion with the C-terminus of the HA tag.
pXJN-HA_Ror1F4 (CDS#1411-2814)K506A, K509A vector
has two mutations in the second basic amino acid cluster
in the Ror1 NLdomain. The mutations include CDS#
1516AAGTGCA and 1525AAATGCA. The fragment was
Figure 6 Quantification of Ror1 localization in transfected cells. The localization pattern of Ror1 in cells expressing the indicated Ror1 and Ran 
constructs was scored for 80 cells. The graph shows the percentage of cells with the indicated Ror1 localization patterns.Tseng et al. BMC Cell Biology 2010, 11:48
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constructed by cloning the 1,404 bp cDNA containing the
cytoplasmic part coding for the sequence of human Ror1
into the HindIII and SmaI site downstream of the CMV
promoter of the pXJN-HA plasmid. The insert is
expressed as fusion with the C-terminus of the HA tag.
pXJN-HA_Ror1F4 (CDS#1411-2814)K486A, K489A, K506A,
K509A vector has four mutations in the first and second
basic amino acids cluster in the Ror1 NLdomain. The
mutations include CDS# 1456AAATGCA, 1465AAA
TGCA, 1516AAGTGCA, and 1525AAATGCA. The frag-
ment was constructed by cloning the 1,404 bp cDNA
containing the cytoplasmic part coding for the sequence
of human Ror1 into the HindIII and SmaI site down-
stream of the CMV promoter of the pXJN-HA plasmid.
The insert is expressed as fusion with the C-terminus of
the HA tag.
All clones were verified by DNA sequencing and west-
ern blotting to confirm the correct sizes of the proteins.
Plasmid transfection
Expression plasmids were transfected into AGS or HR
cells using the Lipofectamine™2000 reagent (11668-500,
Invitrogen) as suggested by the manufacturer but with
some modifications. Briefly, 18 hours before the experi-
ments AGS or HR cells were plated onto coverslips in six-
well culture plates (200,000 cells/well). For the biochemi-
c a l  e x p e r i m e n t s ,  c e l l s  w e r e  p l a t e d  a t  a  h i g h e r  d e n s i t y
(400,000 cells/well). For each transfection, 2 μg of plas-
mid DNA suspended in 50 μl of DMEM was combined
with 2 μl of Lipofectamine2000 suspended in 50 μl of
DMEM and incubated for 20 minutes at room tempera-
ture to allow DNA-liposome complexes to form. Mean-
while, the culture medium was changed to serum-free
DMEM. The mixture was then added dropwise to the
cultures and incubated at 37°C in 5% CO2 for 4-6 hours.
After incubation, the cultures were changed to DMEM
plus 10% fetal bovine serum. The cells were harvested 24
hours after transfection and analyzed.
Immunocytochemistry
The cells seeded on the coverslips were washed with PBS.
AGS or HR cells were fixed for 15 minutes with 3.7%
formaldehyde in PBS and then permeabilized in 0.1% Tri-
ton X-100 in PBS for 5 minutes. The coverslips were pre-
incubated in 5% bovine serum albumin (BSA) in PBS for
20 minutes at 37°C and exposed to the primary antibod-
ies (diluted in 1% BSA + 0.1% Triton X-100 in PBS) for 1
hr at 37°C. Finally, the cultures were rinsed three times in
PBS for 3 minutes and incubated with secondary antibod-
ies for 1 hour at 37°C. After secondary antibodies incuba-
tion, the cultures were washed three times in PBS for 10
minutes and then reserved in the mounting medium
(Vector). The following primary antibodies were used:
HA.11 monoclonal antibody (1:150, MMS-101P, Cova-
nce, Emeryville, CA); Anti-HA polyclonal Y-11 antibody
(1:100, sc-805, Santa Cruz); and anti-Flag monoclonal M2
antibody (1:100, F3165, Sigma). The following secondary
antibodies were used: anti-mouse IgG FITC-conjugated
(1:100, sc-2099, Santa Cruz Biotechnology) and anti-rab-
bit IgG-Rhodamine-conjugated (1:100, sc-2091, Santa
Cruz). To detect actin filaments, cells were stained with
phalloidin rhodamine (1:100, R415, Invitrogen) for 1 hour
at 37°C. As a negative control, one coverslip was incu-
bated without the primary antibody.
Confocal microscopy and image analysis
Confocal images of transfected cells were acquired using
an LSM510 META confocal microscope (Carl Zeiss
MicroImaging, Inc.) with an argon laser operating on a
Nikon Optiphot upright microscope with an oil immer-
sion 60× 1.4NA objective. Optical sections were acquired
at 0.5 mm steps and the XY-pixel size was set at 0.20 mm
using LSM510 v3.5 software (Carl Zeiss MicroImaging)
and later processed using ZEN2007 v4.5.0.124 (Carl Zeiss
MicroImaging). The fluorescence intensity was measured
using MetaMorph Offline v7.1.7.0 (Molecular Devices).
The intensity of the Ror1 fragment-HA-FITC fluores-
cence distribution in the nucleus and cytoplasm was esti-
mated by integrating the average fluorescence intensity
and areas. The noncellular background was estimated
and subtracted from the images before analysis.
Protein electrophoresis and immunoblotting
Cells were rinsed twice in cold PBS and scraped into PBS
buffer, and the pellets were collected in 1.5 mL centrifu-
gation tubes. Cells were lysed with RIPA buffer contain-
ing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-
100, 1% sodium deoxycholate, 0.1% sodium dodecyl sul-
fate (SDS), and freshly added protease inhibitor cocktail
(11697498001, Roche). Next, the protein concentration
was determined using the BioRad protein assay. The pro-
tein sample was separated by SDS-polyacrylamide gels
and electro-blotted to PVDF membrane. The membrane
was blocked with 5% silk milk in TBS containing 0.1%
Tween-20 and incubated with the indicated primary and
secondary antibodies at room temperature. HA.11
monoclonal antibody was used (1:5000; MMS-101P,
Covance). Secondary antibodies conjugated to HRP
(1:5000; Amersham Pharmacia Biotech) followed by
enhanced chemiluminescence reagents (Western Light-
ning™ plus-ECL, PerkinElmer, Inc.) were used to detect
proteins. In some experiments, blots were stripped in
stripping buffer (62.5 mM Tris pH 6.8, 2% SDS, and 100
mM β-mercaptoethanol) at 50°C for 10 minutes, washed
with PBST twice for 10 minutes, and then reprobed with
a different antibody. Membranes were imaged on LAS-Tseng et al. BMC Cell Biology 2010, 11:48
http://www.biomedcentral.com/1471-2121/11/48
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3000 Camera Image Systems (Fujifilm, Tokyo, Japan).
Bands were analyzed using Image J v1.36b (NIH,
Bethesda, MD).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted using TRIzol Reagent (Invitro-
gen) according to the TRIzol Reagent manufacturer's pro-
tocol. Reverse transcription was performed in 20 μl
reactions containing 5 μg of sample RNA, 200 U of
SuperScript™ III reverse transcriptase, 500 ng of
oligo(dT)15, 500 μM dNTP mix, 5 mM DTT, and 1X First-
strand Buffer (Invitrogen). Tubes were incubated at 50°C
for 1 hour and then at 70°C for 15 minutes to terminate
the reaction. The reaction products were then subjected
to PCR amplification. PCR was performed in 25 μl reac-
tions containing RT product, 0.8 μM forward primer (F),
0.8 μM reverse primer (R), deionized water, 0.2 mM
dNTP mixture, 1× PCR buffer (Mg2+ plus), and 0.5 U of
TaKaRa rTaq™ DNA polymerase (TaKaRa). The following
primer sets were used: Ror1-F4 (5'-CCT CAT GAC AGA
GTG CTG GA-3') and Ror1-R2 (5'-TTG TCT GTG TGG
TGG CAT TT-3') corresponding to coding sequences
2,169-2,188 and 2,292-2,311 of the Ror1 human
sequence, respectively; Ror2-F2 (5'-GGG CAA CCT TTC
CAA CTA CA-3') and Ror2-R2 (5'-CGT TGC TCA CAT
TGC TCA CT-3') corresponding to coding sequence
2,247-2,266 and 2,331-2,350 of the Ror2 human
sequence, respectively; and GAPDH-1F (5'-TGG-
TATCGTGGAAGGACTCA-3'), GAPDH-2R (5'-AGTG-
GGTGTCGCTGTTGAAG-3') corresponding to coding
sequence 504-874 of the GAPDH human sequence. For
the Ror1 and Ror2 primer sets, an initial denaturation
time of 5 minutes at 94°C and then 35 cycles (30 seconds
at 94°C, 30 seconds at 54°C/56°C, and 30 seconds at 72°C)
followed by a final extension time of 10 minutes at 72°C
were performed. For the GAPDH primer sets, annealing
temperature was set at 54°C. PCR products were sepa-
rated by electrophoresis on 2% agarose gels in TAE buffer
and visualized with ethidium bromide staining.
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